Prognostic value of residual node involvement in operable breast cancer after induction chemotherapy

Breast Cancer Research and Treatment

Volumn 76, Issue 1, 2002, Pages 37-45

  Curé, Hervé ^a,b   Amat, Sophie ^a,b   Penault Llorca, Frédérique ^a,b   Bouëdec, Guillaume Le ^a   Ferrière, Jean Pierre ^a,b   Mouret Reynier, Marie Ange ^a   Kwiatkowski, Fabrice ^a   Feillel, Viviane ^a   Dauplat, Jacques ^a   Chollet, Philippe ^a,b  

^a CENTRE JEAN PERRIN   (France)

^b INSERM   (France)

Author keywords

Breast cancer; Long term effect; Neoadjuvant chemotherapy; Node involvement; Prognostic factor

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; NAVELBINE; PACLITAXEL; PIRARUBICIN; TAMOXIFEN; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RESIDUAL VOLUME; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL ANALYSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODE EXCISION; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0036838046     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020274709327     Document Type: Article

References (50)

1. Bear HD: Indications for neoadjuvant chemotherapy for breast cancer. Semin Oncol 25: 3-12, 1998
2. Ferriere JP, Assier I, Cure H, Charrier S, Kwiatkowski F, Acbard JL, Dauplat J, Chollet P: Primary chemotherapy in breast cancer: correlation between tumor response and patient outcome. Am J Clin Oncol 21: 117-120, 1998
3. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz Jr AB, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483-2493, 1997
4. Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M, Zambetti M: Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16: 93-100, 1998
5. Calais G, Berger C, Descamps P, Chapet S, Reynaud-Bougnoux A, Body G, Bougnoux P, Lansac J, Le Floch O: Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm. Cancer 74: 1283-1288, 1994
6. Bhalla K, Harris WB: Molecular and biologic determinants of neoadjuvant chemotherapy of locoregional breast cancer. Semin Oncol 25(3): 19-24, 1998
7. Mauriac L, MacGrogan G, Avril A, Durand M, Floquet A, Debled M, Dilbuydy JM, Bonichon F: Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up - Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 10: 47-52, 1999
8. Ragaz J, Baird R, Rebbeck P, Trevisan C, Goldie J, Coldman A: Preoperative (neoadjuvant - PRE) versus postoperative (POST) adjuvant chemotherapy (CT) for stage I-II breast cancer (SI-II BC): long-term analysis of British Columbia randomized trial. Proc ASCO 16: 142a (abstr 499), 1997
9. Semiglazov VF, Topuzov EE, Bavli JL, Moiseyenko VM, Ivanova OA, Seleznev IK, Orlov AA, Barash NY, Golubeva OM, Chepic OF: Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol 5: 591-595, 1994
10. Scholl SM, Fourquet A, Asselain B, Pierga JY, Vilcoq JR, Durand JC, Dorval T, Palangie T, Jouve M, Beuzeboc P, Garcio-Giralt E, Salmon RJ, de la Rochefordière A, Campana F, Pouillart P: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery: preliminary results of randomised trial - S6. Eur J Cancer 30: 645-652, 1994
11. Makris A, Powles TJ, Ashley SE, Chang J, Hickish T, Tidy VA, Nash AG, Ford HT: A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 9: 1179-1184, 1998
12. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz Jrlatex AB, Hoehn JL, Lees AW, Dimitrov NV. Bear HD: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685, 1998
13. Tan B, Piwnica-Worms D, Ratner L: Multidrug resistance transporters and modulation. Curr Opin Oncol 12: 450-458, 2000
14. Hamilton A, Piccart M: The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature of HER-2, p53 and BCL. Ann Oncol 11: 647-663, 2000
15. Nemoto T, Vana J, Bedwani RN, Baker HW, McGregor FH, Murphy GP: Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer 45: 2917-2924, 1980
16. Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER, Cruz AB, Foster R, Gardner B, Lerner H, Margolese R, Poisson R, Shibata H, Volk H, other NSABP investigators: Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. Cancer 52: 1551-1557, 1983
17. Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP, O'Sullivan B, Sobin LH, Yarbro JW (eds): Breast. American Joint Committee on cancer staging manual. 5th edn, Lippincott-Raven, New York, 1997, pp. 171-180
18. Lenert JT, Vlastos G, Mirza NQ, Winchester DJ, Binkley SM, Ames FC, Ross MI, Feig BW, Hunt KK, Strom E, Buzdar AU, Hortobagyi GN, Singletary SE: Primary tumor response to induction chemotherapy as a predictor of histological status of axillary nodes in operable breast cancer patients. Ann Surg Oncol 6(8): 762-767, 1999
19. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17(2): 460-469, 1999
20. Pierga JY, Mouret E, Dieras V, Laurence V, Beuzeboc P, Dorval T, Palangie T, Jouve M, Vincent-Salomon A, Scholl S, Extra JM, Asselain B, Pouillart P: Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer 83(11): 1480-1487, 2000
21. Forrest AP, Levack PA, Chetty U, Hawkins RA, Miller WR, Smyth JF, Anderson TJ: A human tumor model. Lancet 2: 840-842, 1986
22. Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeese MD, Paulus D, Hug V, Holmes FA, Romsdahl MM, Fraschini G, McBride CM, Martin RG, Montague E: Management of stage III primary breast cancer with primary chemotherapy, surgery and radiation therapy. Cancer 62: 2507-2516, 1988
23. Hortobagyi GN, Buzdar AU, Strom EA, Ames FC, Singletary SE: Primary chemotherapy for early and advanced breast cancer. Cancer Lett 90: 103-109, 1995
24. Jacquillat C, Weil M, Baillet F, Borel C, Auclerc G, de Maublanc MA, Housset M, Forget G, Thill L, Soubrane C, Khayat D: Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 66: 119-129, 1990
25. Smith IE, Walsh G, Jones A, Prendiville J, Johnston S, Gusterson B, Ramage F, Robertshaw H, Sacks N, Ebbs S, McKinna JA, Baum M: High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 13: 424-429, 1995
26. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410, 1991
27. Belembaogo E, Feillel V, Chollet P, Cure H, Verelle P, Kwiatkowski F, Achard JL, le Bouëdec G, Chassagne J, Bignon YJ, de Latour M, Lafaye C, Dauplat J: Neoadjuvant chemotherapy in 126 operable breast cancers. Eur J Cancer 28A(4/5): 896-900, 1992
28. Van Praagh I, Leduc B, Feillel V, Curé H, Bichoffe A, Charrier S, Le Bouëdec G, Achard JL, de Latour M, Dauplat J, Le Bras F, Chollet P: Neoadjuvant VEM chemotherapy regimen for operable breast cancer: results of a cooperative study on 69 patients. Proc ASCO 14: 136 (abstr 242), 1995
29. Chollet P, Charrier S, Brain E, Cure H, Van Praagh I, Feillel V, de Latour M, Dauplat J, Misset JL, Ferriere JP: Clinical and pathological response to primary chemotherapy in operable breast cancer. Eur J Cancer 33: 862-866, 1997
30. Chollet P, Amat S, Penault-Llorca F, Fetissof F, Body G, Mouret-Reynier MA, Bons JM, Cure H, Dauplat J, Bougnoux P: High pathological response rate induced by primary docetaxel monotherapy in operable breast cancer. Breast Cancer Res Treat 64: 67 (abstr 251), 2000
31. Van Praagh I, Amat S, Delva R, Leduc B, Mouret-Reynier MA, Lortholary A, Sillet-Bach I, Fleury J, Bonnel C, Feillel V, Penault-Llorca F, Le Bouëdec G, Chollet P: Induction chemotherapy in operable breast cancer by NET regimen: multicenter phase II trial. Proc ASCO 20: 35b (abstr 1889), 2001
32. Miller A, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
33. Chevallier B, Roché H, Olivier JP, Chollet P, Hurteloup P: Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD). Results in a high histologic response rate. Am J Clin Oncol 16: 223-228, 1993
34. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. Clinical course of breast cancer. J Am Stat Assoc 185: 1457-1481, 1958
35. Mantel N: Evaluation of survival data and two row rank order statistics arising in its consideration. Cancer Chemother Rep 50(3): 163-170, 1966
36. Cox DR: Regression models and life tables. JR Stat Soc B 34: 187-202, 1972
37. Kuerer HM, Newman LA, Buzdar AU, Hunt KK, Dhingra K, Buchholz TA, Binkley SM, Ames FC, Feig BW, Ross MI, Hortobagyi GN, Singletary SE: Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary node status. Cancer J Sci Am 4: 230-236, 1998
38. Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, Bartoli C, Coopmans de Yoldi G, Zucali R, Rilke F, Andreola S, Silvestrini R, Di Fronzo G, Valagussa P: Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82: 1539-1545, 1990
39. Schwartz GF, Birchansky CA, Komarnicky LT, Mansfield CM, Cantor RI, Biermann WA: Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 73: 362-369, 1994
40. McCready DR, Hortobagyi GN, Kau SW, Smith TL, Buzdar AU, Balch CM: The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg 124(1): 21-25, 1989
41. Gardin G, Rosso R, Campora E, Repetto L, Naso C, Canavese G, Catturich A, Corvo R, Guenzi M, Pronzato P, Baldini E, Conte PF: Locally advanced non-metastatic breast cancer: analysis of prognostic factors in 125 patients homogeneously treated with a combined modality approach. Eur J Cancer 31 A: 1428-1433, 1995
42. Machiavelli MR, Romero AO, Perez JE, Lacava JA, Dominguez ME, Rodriguez R, Barbieri MR, Romero Acuna LA, Romero Acuna JM, Langhi MJ, Amato S, Ortiz EH, Vallejo CT, Leone BA: Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 4: 125-131, 1998
43. Ellis P, Smith I, Ashley S, Walsh G, Ebbs S, Baum M, Sacks N, McKinna J: Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol 16: 107-114, 1998
44. Cameron DA, Anderson ED, Levack P, Hawkins RA, Anderson TJ, Leonard RC, Forrest AP, Chetty U: Primary systemic therapy for operable breast cancer - 10-year survival data after chemotherapy and hormone therapy. Br J Cancer 76: 1099-1105, 1997
45. Botti C, Vici P, Lopez M, Scinto AF, Cognetti F, Cavaliere R: Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast. J Am Coll Surg 181: 202-208, 1995
46. Scholl SM, Pierga JY, Asselin B, Beuzeboc P, Dorval T, Garcia-Giralt E, Jouve M, Palangie T, Remvikos Y, Durand JC, Fourquet A, Pouillart P: Breast turnout response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 31A(12): 1969-1975, 1995
47. Feldman LD, Hortobagyi GN, Buzdar AV, Ames FC, Blumenschein GR: Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 46: 2578-2581, 1986
48. Brain E, Misset JL, Rouessé J: Initial medical treatment for breast cancer. Bull Cancer 86(9): 745-752, 1999
49. Fisher B, Wolmark N, Redmond C, Deutsch M, Fisher ER, participating NSABP investigators: Findings from NSABP protocol No. B-04: comparison of radical mastectomy with alternative treatments. II. The clinical and biologic significance of medial-center breast cancers. Cancer 48: 1863-1872, 1981
50. D'Orazio AI: Neoadjuvant docetaxel augments the efficacy of preoperative docetaxel/cyclophosphamide in operable breast cancer: first results of NSABP B-27. Clin Breast Cancer 2(4): 266-268, 2002